DelveInsight’s “Hepatitis C Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Hepatitis C, historical and forecasted epidemiology as well as the Hepatitis C market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Hepatitis C, offering comprehensive insights into the Hepatitis C revenue trends, prevalence, and treatment landscape. The report delves into key Hepatitis C statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Hepatitis C therapies. Additionally, we cover the landscape of Hepatitis C clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Hepatitis C treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Hepatitis C space.
To Know in detail about the Hepatitis C market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hepatitis C Market Forecast
Some of the key facts of the Hepatitis C Market Report:
The Hepatitis C market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In July 2024, The World Health Organization (WHO) has prequalified the first self-test for hepatitis C, a disease caused by the hepatitis C virus (HCV) that impacts the liver. The virus can lead to both acute and chronic hepatitis, with symptoms ranging from mild illness to severe, lifelong conditions such as liver cirrhosis and cancer. Hepatitis C is bloodborne, with most infections resulting from exposure to blood through unsafe injection practices, unregulated healthcare procedures, blood transfusions, drug injection use, or blood exposure.
In June 2024, The FDA approved Cepheid’s Xpert HCV test and GeneXpert Xpress System, representing a major breakthrough in Hepatitis C diagnostics by streamlining the process with a faster, test-and-treat method compared to conventional multi-step testing.
In 2023, the Hepatitis C Virus (HCV) market in the United States was valued at approximately USD 2,000 million.
In 2023, Genotype 1 represented around 70% of genotype-specific diagnosed Hepatitis C cases in the United States, emphasizing its high prevalence and the need for targeted treatment approaches.
The treatment of Hepatitis C has been revolutionized by direct-acting antivirals (DAAs) like HARVONI and Epclusa from Gilead Sciences, as well as VIEKIRA PAK from AbbVie, which provide high cure rates by targeting different stages of the virus. The introduction of MAVYRET by AbbVie in 2017 further broadened treatment options, strengthening global efforts to eliminate Hepatitis C.
Hepatitis C is a viral infection that primarily targets the liver, potentially causing acute and chronic liver disease if left untreated. Worldwide, nearly 50 million people live with chronic Hepatitis C, with around 1 million new cases each year. According to the WHO, approximately 242,000 deaths in 2022 were linked to Hepatitis C, mainly due to cirrhosis and hepatocellular carcinoma.
Key Hepatitis C Therapies: MAVYRET (Glecaprevir and Pibrentasvir), VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir), EPCLUSA, Bemnifosbuvir + Ruzasvir, and others
Key Hepatitis C Companies: AbbVie, Gilead Sciences, Atea Pharmaceuticals, and others
Direct-acting antivirals (DAAs) like HARVONI and Epclusa from Gilead Sciences, and VIEKIRA PAK from AbbVie, have revolutionized Hepatitis C treatment by providing high cure rates and targeting different stages of the virus. AbbVie’s MAVYRET, launched in 2017, broadened treatment options, significantly contributing to the global initiative to eradicate Hepatitis C.
The Hepatitis C market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hepatitis C pipeline products will significantly revolutionize the Hepatitis C market dynamics.
In 2023, approximately 2.1 million diagnosed cases of Hepatitis C were recorded in the United States.
In the same year, males accounted for roughly 60% of the cases in the EU4 countries and the UK.
In Japan, individuals aged 46-55 represented approximately 70% of Hepatitis C cases in 2023.
Hepatitis C Overview
Hepatitis C is a viral infection caused by the Hepatitis C virus (HCV) that primarily affects the liver. It can lead to both acute and chronic liver disease, including cirrhosis, liver failure, and liver cancer if left untreated. The virus spreads through blood-to-blood contact, often via shared needles, unsterile medical equipment, or transfusions of unscreened blood.
Get a Free sample for the Hepatitis C Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hepatitis-c-market
Hepatitis C Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hepatitis C Epidemiology Segmentation:
The Hepatitis C market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Hepatitis C
Prevalent Cases of Hepatitis C by severity
Gender-specific Prevalence of Hepatitis C
Diagnosed Cases of Episodic and Chronic Hepatitis C
Download the report to understand which factors are driving Hepatitis C epidemiology trends @ Hepatitis C Epidemiology Forecast
Hepatitis C Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hepatitis C market or expected to get launched during the study period. The analysis covers Hepatitis C market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hepatitis C Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hepatitis C Therapies and Key Companies
MAVYRET (Glecaprevir and Pibrentasvir): AbbVie
VOSEVI (sofosbuvir, velpatasvir, and voxilaprevir): Gilead Sciences
EPCLUSA: Gilead Sciences
Bemnifosbuvir + Ruzasvir: Atea Pharmaceuticals
Discover more about therapies set to grab major Hepatitis C market share @ Hepatitis C Treatment Landscape
Hepatitis C Market Drivers
Advancements in Antiviral Treatments
Increased Screening and Early Detection
Government Initiatives
Improved Patient Access
Global Collaboration
Rising Awareness
Hepatitis C Market Barriers
High Treatment Costs
Geographical Disparities
Stigma and Lack of Awareness
Complicated Diagnosis in Early Stages
Co-infection with Other Diseases
Limited Healthcare Infrastructure
Scope of the Hepatitis C Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Hepatitis C Therapeutic Assessment: Hepatitis C current marketed and Hepatitis C emerging therapies
Hepatitis C Market Dynamics: Hepatitis C market drivers and Hepatitis C market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Hepatitis C Unmet Needs, KOL’s views, Analyst’s views, Hepatitis C Market Access and Reimbursement
To know more about Hepatitis C companies working in the treatment market, visit @ Hepatitis C Clinical Trials and Therapeutic Assessment
Table of Contents
1. Hepatitis C Market Report Introduction
2. Executive Summary for Hepatitis C
3. SWOT analysis of Hepatitis C
4. Hepatitis C Patient Share (%) Overview at a Glance
5. Hepatitis C Market Overview at a Glance
6. Hepatitis C Disease Background and Overview
7. Hepatitis C Epidemiology and Patient Population
8. Country-Specific Patient Population of Hepatitis C
9. Hepatitis C Current Treatment and Medical Practices
10. Hepatitis C Unmet Needs
11. Hepatitis C Emerging Therapies
12. Hepatitis C Market Outlook
13. Country-Wise Hepatitis C Market Analysis (2020–2034)
14. Hepatitis C Market Access and Reimbursement of Therapies
15. Hepatitis C Market Drivers
16. Hepatitis C Market Barriers
17. Hepatitis C Appendix
18. Hepatitis C Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
